Differential RNA expression profile by cDNA microarray in sporadic primary hyperparathyroidism (pHPT): Primary parathyroid hyperplasia versus adenoma

World Journal of Surgery

Volumn 30, Issue 5, 2006, Pages 705-713

  Velázquez Fernández, David ^a   Laurell, Cecilia ^b   Saqui Salces, Milena ^a   Pantoja, Juan Pablo ^a   Candanedo Gonzalez, Fernando ^a   Reza Albarrán, Alfredo ^a   Gamboa Dominguez, Armando ^a   Herrera, Miguel F ^a  

^a INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

^b ROYAL INSTITUTE OF TECHNOLOGY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; RNA;

ARTICLE; CLINICAL ARTICLE; DIFFERENTIAL DIAGNOSIS; DNA MICROARRAY; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPERPARATHYROIDISM; PARATHYROID ADENOMA; PARATHYROID TUMOR; PARATHYROIDECTOMY; PRIMARY HYPERPARATHYROIDISM; PROGNOSIS; TUMOR DIAGNOSIS;

ADENOMA; DIAGNOSIS, DIFFERENTIAL; GENE EXPRESSION PROFILING; HUMANS; HYPERPARATHYROIDISM, PRIMARY; HYPERPLASIA; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PARATHYROID NEOPLASMS; RNA;

EID: 33646597240     PISSN: 03642313     EISSN: 14322323     Source Type: Journal    
DOI: 10.1007/s00268-005-0708-3     Document Type: Article

References (49)

1. Kinder BK, Stewart AF. Hypercalcemia. Current Prob Surg 2002;39:445.
2. Bilezikian JP, Brandi ML, Rubin M, et al. Primary hyperparathyroidism: new concepts in clinical, densitometric and biochemical features. J Intern Med 2005;257:6-17.
3. Utiger RD. Treatment of primary hyperparathyroidism. N Engl J Med 1999;341:1301-1302.
4. Caron NR, Sturgeon C, Clark OH. Persistent and recurrent hyperparathyroidism. Curr Treat Options Oncol 2004;5:335-345.
5. Lee JA, Inabnet WB, 3rd. The surgeon's armamentarium to the surgical treatment of primary hyperparathyroidism. J Surg Oncol 2005;89:130-135.
6. Milas M, Wagner K, Easley KA, et al. Double adenomas revisited: nonuniform distribution favors enlarged superior parathyroids (fourth pouch disease). Surgery 2003;134:995-1003; discussion 1003-1004.
7. Chen H, Mack E, Starling JR. A comprehensive evaluation of perioperative adjuncts during minimally invasive parathyroidectomy: which is most reliable? Ann Surg 2005;242:375-380.
8. Grant CS, Thompson G, Farley D, et al. Primary hyperparathyroidism surgical management since the introduction of minimally invasive parathyroidectomy: Mayo Clinic experience. Arch Surg 2005;140:472-478.
9. Bornstein-Quevedo L, Gamboa-Domínguez A, Angeles-Angeles A, et al. Histologic diagnosis of primary hyperparathyroidism: a concordance analysis between three pathologists. Endocr Pathol 2001;12:49-54.
10. Correa P , Juhlin C , Rastad J , et al. Allelic loss in clinically and screening-detected primary hyperparathyroidism. Clin Endocrinol (Oxf) 2002;56:113-117.
11. Mallya SM, Gallagher JJ, Arnold A. Analysis of microsatellite instability in sporadic parathyroid adenomas. J Clin Endocrinol Metab 2003;88:1248-1251.
12. Silver J.. Cycling with the parathyroid. J Clin Invest 2001;107:1079-1080.
13. Imanishi Y, Hosokawa Y, Yoshimoto K, et al. Primary hyperparathyroidism caused by parathyroid-targeted overexpression of cyclin D1 in transgenic mice. J Clin Invest 2001;107:1093.
14. Agarwal SK, Schrock E, Kester MB, et al. Comparative genomic hybridization analysis of human parathyroid tumors. Cancer Genet Cytogenet 1998;106:30-36.
15. Schachter PP , Ayesh S , Schneider T , et al. Expression of kinase genes in primary hyperparathyroidism: adenoma versus hyperplastic parathyroid tissue. Surgery 2002;132:1094-1098; discussion 1098-1099.
16. Garcia JL , Tardio JC , Gutierrez NC , et al. Chromosomal imbalances identified by comparative genomic hybridization in sporadic parathyroid adenomas. Eur J Endocrinol 2002;146:209-213.
17. Stojadinovic A, Hoos A, Nissan A, et al. Parathyroid neoplasms: clinical, histopathological, and tissue microarray-based molecular analysis. Hum Pathol 2003;34:54-64.
18. Giordano TJ. Gene expression profiling of endocrine tumors using DNA microarrays: progress, promise. Endocr Pathol 2003;14:107-116.
19. Barden CB, Shister KW, Zhu B, et al. Classification of follicular thyroid tumors by molecular signature: results of gene profiling. Clin Cancer Res 2003;9:1792-1800.
20. Mohr S, Leikauf GD, Keith G, et al. Microarrays as cancer keys: an array of possibilities. J Clin Oncol 2002;20:3165-3175.
21. Hedenfalk I, Duggan D, Chen Y, et al. Gene-expression profiles in hereditary breast cancer. N Engl J Med 2001;344:539-548.
22. Kim J, Yang P, Suraokar M, et al. Suppression of prostate tumor cell growth by stromal cell prostaglandin D synthase-derived products. Cancer Res 2005;65:6189-6198.
23. Garcia V, Furuya K, Carr AM. Identification and functional analysis of TopBP1 and its homologs. DNA Repair (Amst) 2005;4:1227-1239.
24. Murakawa T, Tsuda H, Tanimoto T, et al. Expression of KIT, EGFR, HER-2 and tyrosine phosphorylation in undifferentiated thyroid carcinoma: implication for a new therapeutic approach. Pathol Int 2005;55:757-765.
25. Li F, Cao Y, Townsend CM Jr, et al. TGF-beta signaling in colon cancer cells. World J Surg 2005;29:306-311.
26. Weimer JM, Chattopadhyay S, Custer AW, et al. Elevation of Hook1 in a disease model of Batten disease does not affect a novel interaction between Ankyrin G and Hook1. Biochem Biophys Res Commun 2005;330:1176-1181.
27. Zhao P, Liu W, Lu YL. Clinicopathological significance of FHIT protein expression in gastric adenocarcinoma patients. World J Gastroenterol 2005;11:5735-5738.
28. Watkins G, Douglas-Jones A, Mansel RE, et al. Expression of thromboxane synthase, TBXAS1 and the thromboxane A2 receptor, TBXA2R, in human breast cancer. Int Semin Surg Oncol 2005;2:23.
29. Mattera R, Arighi CN, Lodge R, et al. Divalent interaction of the GGAs with the Rabaptin-5-Rabex-5 complex. EMBO J 2003;22:78-88.
30. Shiratori A, Okumura K, Nogami M, et al. Assignment of the 49-kDa (PRIM1) and 58-kDa (PRIM2A and PRIM2B) subunit genes of the human DNA primase to chromosome bands 1q44 and 6p11.1-p12. Genomics 1995;28:350-353.
31. Cella M, Buonsanti C, Strader C, et al. Impaired differentiation of osteoclasts in TREM-2-deficient individuals. J Exp Med 2003;198:645-651.
32. Paloneva J, Mandelin J, Kiialainen A. DAP12/TREM2 deficiency results in impaired osteoclast differentiation and osteoporotic features. J Exp Med 2003;198:669-675.
33. Tseng WW, Liu CD. Peptide YY and cancer: current findings and potential clinical applications. Peptides 2002;23:389-395.
34. Liu CD, Rongione AJ, Garvey L, et al. Adjuvant hormonal treatment with peptide YY or its analog decreases human pancreatic carcinoma growth. Am J Surg 1996;171:192-196.
35. Heisler T, Towfigh S, Simon N, et al. Peptide YY augments gross inhibition by vitamin E succinate of human pancreatic cancer cell growth. J Surg Res 2000;88:23-25.
36. Grise KR, Rongione AJ, Laird EC, et al. Peptide YY inhibits growth of human breast cancer in vitro and in vivo. J Surg Res 1999;82:151-155.
37. Heisler T, Towfigh S, Simon N, et al. Peptide YY and vitamin E inhibit hormone-sensitive and -insensitive breast cancer cells. J Surg Res 2000;91:9-14.
38. Koch-Nolte F, Glowacki G, Bannas P, et al. Use of genetic immunization to raise antibodies recognizing toxin-related cell surface ADP-ribosyltransferases in native conformation. Cell Immunol 2005;236:66-71.
39. Noguchi T, Takeno S, Kimura Y, et al. FHIT expression and hypermethylation in esophageal squamous cell carcinoma. Int J Mol Med 2003;11:441-447.
40. Xiao YP, Han CB, Mao XY, et al. Relationship between abnormality of FHIT gene and EBV infection in gastric cancer. World J Gastroenterol 2005;11:3212-3216.
41. Luceri C, Guglielmi F, De Filippo C, et al. Clinicopathologic features and FHIT gene expression in sporadic colorectal adenocarcinomas. Scand J Gastroenterol 2000;35: 637-641.
42. Gabrilovich DI, Cheng P, Fan Y, et al. H1(0) histone and differentiation of dendritic cells. A molecular target for tumor-derived factors. J Leukocyte Biol 2002;72:285-296.
43. Haven CJ, Howell VM, Eilers PH, et al. Gene expression of parathyroid tumors: molecular subclassification and identification of the potential malignant phenotype. Cancer Res 2004;64:7405-7411.
44. Corbetta S, Lania A, Filopanti M, et al. Mitogen-activated protein kinase cascade in human normal and tumoral parathyroid cells. J Clin Endocrinol Metab 2002;87:2201-2205.
45. Rosen JE, Costouros NG, Lorang D, et al. Gland size is associated with changes in gene expression profiles in sporadic parathyroid adenomas. Ann Surg Oncol 2005;12:412-416.
46. Al-Shahrour F, Diaz-Uriarte R, Dopazo J. Discovering molecular functions significantly related to phenotypes by combining gene expression data and biological information. Bioinformatics 2005;21:2988-2993.
47. Smid M, Dorssers LC. GO-Mapper: functional analysis of gene expression data using the expression level as a score to evaluate Gene Ontology terms. Bioinformatics 2004;20:2618-2625.
48. Liang Y, Kelemen A. Associating phenotypes with molecular events: recent statistical advances and challenges underpinning microarray experiments. Funct Integr Genomics 2005;15:1-13.
49. Morrison JL, Breitling R, Higham DJ, et al. GeneRank: using search engine technology for the analysis of microarray experiments. BMC Bioinformatics 2005;6:233.